Beyond Pay-For-Delay: US FTC Digs Deeper On Barriers To Generic Competition
Executive Summary
FTC Acting Chairman Ohlhausen predicts agency will continue to focus on competition issues involving barriers to generics but says 'we need to learn more about how these markets are working today.'
You may also be interested in...
FDA And FTC Join Forces On Biosimilars
Two agencies to take action against false or misleading communications about biosimilars, impediments to sampling, and anticompetitive patent settlement agreements; to hold public workshop in March.
FDA, FTC Join Forces To Eliminate Barriers To Biosimilar Competition
Two agencies to take action against false or misleading communications about biosimilars, impediments to sampling, and anticompetitive patent settlement agreements; to hold public workshop in March.
Will Slew of Patent Bills Lower Drug Prices?
Legislation is targeting a wide range of patent practices, from product hopping to patent infringement settlements and inter partes review.